Hematological and renal responses
| . | All patients (N = 50) . | Chemotherapy (N = 29) . | Others (IS/conservative) (N = 21) . | P value . |
|---|---|---|---|---|
| Hematological response, n (%) | 18/49 (37%) | 17/29 (59%) | 1 /20 (5%) | .0002* |
| Complete response | 9 (18%) | 8 (28%) | 1 (5%) | .06† |
| Very good partial response | 1 (2%) | 1 (3%) | 0 (0%) | 1‡ |
| Partial response | 8 (16%) | 8 (28%) | 0 (0%) | .01¶ |
| No response | 31 (63%) | 12 (41%) | 19 (95%) | .0002§ |
| NA | 1 (2%) | 1 (%5) | 1 | |
| Severe adverse events | 6 (12%) | 5 (21%) | 1 (5%) | .21 |
| Renal response, n (%) | 20/48 (42%) | 19/27 (74%) | 1/21 (5%) | .0001 |
| Complete response | 6 (13%) | 6 (22%) | 0 (0%) | .001 |
| Partial response | 14 (29%) | 13 (48%) | 1 (5%) | .002 |
| No response | 28 (58%) | 9 (32%) | 19 (90%) | .0001 |
| NA | 2 (4%) | 2 (6%) | 0 (0%) | — |
| Renal parameters after first-line therapy | ||||
| Serum creatinine, µmol/L | 179 (70-450) | 147 (70-450) | 231 (132-400) | .17 |
| eGFR, mL/min/1.73m2 | 34 (16-94) | 37 (16-94) | 24 (16-51) | .1 |
| 24-h Proteinuria, g | 2.4 (0.1-5) | 2.4 (0.1-3) | 2.6 (0.7-5) | .46 |
| ESRD, n (%) | 12 (24%) | 5 (17%) | 7 (33%) | .31 |
| Data at last follow-up | ||||
| Follow-up, mo | 24 (4-104) | 24 (8-104) | 25 (4-69) | .75 |
| Serum creatinine, µmol/L | 144 (68-290) | 135 (68-258) | 249 (135-290) | .2 |
| eGFR, ml/min/1.73 m2 | 38 (18-89) | 38 (18-89) | 21 (19-48) | .16 |
| 24-h proteinuria, g | 1.1 (0.08-6.5) | 0.86 (0.08-17) | 1.2 (0.4-7) | .59 |
| ESRD, n (%) | 25 (50%) | 9 (31%) | 16 (76%) | .003 |
| Renal transplantation, n (%) | 4 (8%) | 0 (0%) | 4 (13%) | — |
| C3G recurrence, n (%) | 4/4 (100%) | — | 4/4 (100%) | — |
| Death, n (%) | 5 (10%) | 3 (10%) | 2 (10%) | 1 |
| . | All patients (N = 50) . | Chemotherapy (N = 29) . | Others (IS/conservative) (N = 21) . | P value . |
|---|---|---|---|---|
| Hematological response, n (%) | 18/49 (37%) | 17/29 (59%) | 1 /20 (5%) | .0002* |
| Complete response | 9 (18%) | 8 (28%) | 1 (5%) | .06† |
| Very good partial response | 1 (2%) | 1 (3%) | 0 (0%) | 1‡ |
| Partial response | 8 (16%) | 8 (28%) | 0 (0%) | .01¶ |
| No response | 31 (63%) | 12 (41%) | 19 (95%) | .0002§ |
| NA | 1 (2%) | 1 (%5) | 1 | |
| Severe adverse events | 6 (12%) | 5 (21%) | 1 (5%) | .21 |
| Renal response, n (%) | 20/48 (42%) | 19/27 (74%) | 1/21 (5%) | .0001 |
| Complete response | 6 (13%) | 6 (22%) | 0 (0%) | .001 |
| Partial response | 14 (29%) | 13 (48%) | 1 (5%) | .002 |
| No response | 28 (58%) | 9 (32%) | 19 (90%) | .0001 |
| NA | 2 (4%) | 2 (6%) | 0 (0%) | — |
| Renal parameters after first-line therapy | ||||
| Serum creatinine, µmol/L | 179 (70-450) | 147 (70-450) | 231 (132-400) | .17 |
| eGFR, mL/min/1.73m2 | 34 (16-94) | 37 (16-94) | 24 (16-51) | .1 |
| 24-h Proteinuria, g | 2.4 (0.1-5) | 2.4 (0.1-3) | 2.6 (0.7-5) | .46 |
| ESRD, n (%) | 12 (24%) | 5 (17%) | 7 (33%) | .31 |
| Data at last follow-up | ||||
| Follow-up, mo | 24 (4-104) | 24 (8-104) | 25 (4-69) | .75 |
| Serum creatinine, µmol/L | 144 (68-290) | 135 (68-258) | 249 (135-290) | .2 |
| eGFR, ml/min/1.73 m2 | 38 (18-89) | 38 (18-89) | 21 (19-48) | .16 |
| 24-h proteinuria, g | 1.1 (0.08-6.5) | 0.86 (0.08-17) | 1.2 (0.4-7) | .59 |
| ESRD, n (%) | 25 (50%) | 9 (31%) | 16 (76%) | .003 |
| Renal transplantation, n (%) | 4 (8%) | 0 (0%) | 4 (13%) | — |
| C3G recurrence, n (%) | 4/4 (100%) | — | 4/4 (100%) | — |
| Death, n (%) | 5 (10%) | 3 (10%) | 2 (10%) | 1 |
Specific comparison between the group chemotherapy and IS therapy: *P = .08; †P = .65; ‡P = 1; ¶P = .3; and §P = .08.
g, gramme; NA, not available.